# US 10,870,673 B2 · β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,673 B2
- Document ID: US10870673B2
- Status: Granted
- Kind: B2
- Application number: 16/918,898
- Filed: 2020-07-01
- Published: 2020-10-22
- Granted: 2020-12-22
- Earliest claimed: 2015-03-06
- Assignees: Atea Pharmaceuticals, Inc.
- Applicants: Atea Pharmaceuticals, Inc.
- Inventors: Jean-Pierre Sommadossi; Adel Moussa
- Web page: https://patentgrep.com/patent/US10870673B2

## CPC

- C07H 19/207: the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 31/14: for RNA viruses
- C07H 19/16: Purine radicals
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

## Claims

### Claim 1

A compound of the formula
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising an effective therapeutic amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, in an oral dosage form.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the oral dosage form is a solid dosage form.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the solid dosage form is a tablet.

### Claim 6 (depends on 4)

The pharmaceutical composition of claim 4, wherein the solid dosage form is a capsule.

### Claim 7 (depends on 3)

The pharmaceutical composition of claim 3, wherein the oral dosage form is a liquid dosage form.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the liquid dosage form is a suspension or solution.

### Claim 9 (depends on 2)

The pharmaceutical composition of claim 2, in an intravenous formulation.

### Claim 10 (depends on 2)

The pharmaceutical composition of claim 2, in a parenteral formulation.

### Claim 11

A compound of the formula
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

A pharmaceutical composition comprising an effective therapeutic amount of a compound of claim 11 or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, in an oral dosage form.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the oral dosage form is a solid dosage form.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the solid dosage form is a tablet.

### Claim 16 (depends on 14)

The pharmaceutical composition of claim 14, wherein the solid dosage form is a capsule.

### Claim 17 (depends on 13)

The pharmaceutical composition of claim 13, wherein the oral dosage form is a liquid dosage form.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the liquid dosage form is a suspension or solution.

### Claim 19 (depends on 12)

The pharmaceutical composition of claim 12, in an intravenous formulation.

### Claim 20 (depends on 12)

The pharmaceutical composition of claim 12, in a parenteral formulation.

### Claim 21

A compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein the compound is at least 90% free of the opposite phosphorus R-enantiomer.

### Claim 22 (depends on 21)

The compound of claim 21, wherein the compound is at least 98% free of the opposite phosphorus R-enantiomer.

### Claim 23 (depends on 21)

The compound of claim 21, wherein the compound is at least 99% free of the opposite phosphorus R-enantiomer.

### Claim 24

A pharmaceutical composition comprising an effective therapeutic amount of a compound of the formula
or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier, wherein the compound is at least 90% free of the opposite phosphorus R-enantiomer.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the compound is at least 98% free of the opposite phosphorus R-enantiomer.

### Claim 26 (depends on 24)

The pharmaceutical composition of claim 24, wherein the compound is at least 99% free of the opposite phosphorus R-enantiomer.

### Claim 27 (depends on 24)

The pharmaceutical composition of claim 24, in an oral dosage form.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the oral dosage form is a solid dosage form.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein the solid dosage form is a tablet.

### Claim 30 (depends on 28)

The pharmaceutical composition of claim 28, wherein the solid dosage form is a capsule.

### Claim 31 (depends on 27)

The pharmaceutical composition of claim 27, wherein the oral dosage form is a liquid dosage form.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the liquid dosage form is a suspension or solution.

### Claim 33 (depends on 24)

The pharmaceutical composition of claim 24, in an intravenous formulation.

### Claim 34 (depends on 24)

The pharmaceutical composition of claim 24, in a parenteral formulation.